Ownership Action to Note: Quest Diagnostics Inc (NYSE:DGX) Institutional Investor Sentiment Analysis

November 28, 2016 - By Hazel Jackson   ·   0 Comments

Ownership Action to Note: Quest Diagnostics Inc (NYSE:DGX) Institutional Investor Sentiment Analysis

Sentiment for Quest Diagnostics Inc (NYSE:DGX)

Quest Diagnostics Inc (NYSE:DGX) institutional sentiment decreased to 0.92 in 2016 Q2. Its down -0.15, from 1.07 in 2016Q1. The ratio is negative, as 223 funds increased and started new positions, while 208 reduced and sold their holdings in Quest Diagnostics Inc. The funds in our partner’s database reported: 124.00 million shares, down from 133.41 million shares in 2016Q1. Also, the number of funds holding Quest Diagnostics Inc in their top 10 positions increased from 7 to 8 for an increase of 1. Sold All: 35 Reduced: 173 Increased: 168 New Position: 55.

Quest Diagnostics Incorporated is a well-known provider of diagnostic information services. The company has a market cap of $12.31 billion. The Firm operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. It has a 18.7 P/E ratio. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations , integrated delivery networks (IDNs), other commercial laboratories, employers and others.

The stock increased 0.57% or $0.5 on November 25, hitting $88.32. Quest Diagnostics Inc (NYSE:DGX) has risen 17.20% since April 25, 2016 and is uptrending. It has outperformed by 11.18% the S&P500.

Analysts await Quest Diagnostics Inc (NYSE:DGX) to report earnings on January, 26. They expect $1.28 EPS, up 7.56% or $0.09 from last year’s $1.19 per share. DGX’s profit will be $178.41M for 17.25 P/E if the $1.28 EPS becomes a reality. After $1.37 actual EPS reported by Quest Diagnostics Inc for the previous quarter, Wall Street now forecasts -6.57% negative EPS growth.

According to Zacks Investment Research, “Quest Diagnostics Inc., is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.”

Healthcare Value Capital Llc holds 6.53% of its portfolio in Quest Diagnostics Inc for 66,208 shares. Healthcor Management L.P. owns 1.15 million shares or 5.11% of their US portfolio. Moreover, Randolph Co Inc has 4.9% invested in the company for 234,100 shares. The California-based Poplar Forest Capital Llc has invested 4.54% in the stock. Sarissa Capital Management Lp, a Connecticut-based fund reported 159,000 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 insider buys, and 5 selling transactions for $4.94 million net activity.

Quest Diagnostics Inc (NYSE:DGX) Ratings Coverage

Ratings analysis reveals 22% of Quest Diagnostics’s analysts are positive. Out of 9 Wall Street analysts rating Quest Diagnostics, 2 give it “Buy”, 1 “Sell” rating, while 6 recommend “Hold”. The lowest target is $68 while the high is $90. The stock’s average target of $79 is -10.55% below today’s ($88.32) share price. DGX was included in 16 notes of analysts from August 4, 2015. The rating was maintained by RBC Capital Markets on Friday, January 29 with “Sector Perform”. RBC Capital Markets maintained Quest Diagnostics Inc (NYSE:DGX) rating on Friday, October 23. RBC Capital Markets has “Sector Perform” rating and $70 price target. On Monday, November 14 the stock rating was upgraded by UBS to “Buy”. Citigroup initiated Quest Diagnostics Inc (NYSE:DGX) on Friday, September 9 with “Neutral” rating. The company was downgraded on Wednesday, August 31 by Mizuho. Canaccord Genuity maintained the shares of DGX in a report on Friday, November 13 with “Buy” rating. The rating was maintained by Mizuho with “Neutral” on Thursday, October 22. The stock has “Hold” rating given by Zacks on Tuesday, August 18. The stock of Quest Diagnostics Inc (NYSE:DGX) has “Neutral” rating given on Friday, October 21 by Mizuho. On Friday, October 16 the stock rating was upgraded by Wells Fargo to “Market Perform”.

DGX Company Profile

Quest Diagnostics Incorporated, incorporated on September 20, 1996, is a well-known provider of diagnostic information services. The Firm operates through two businesses: Diagnostic Information Services and Diagnostic Solutions.

More recent Quest Diagnostics Inc (NYSE:DGX) news were published by: Wsj.com which released: “UnitedHealth’s Optum Unit to Oversee Quest Diagnostics’ Billing Processes” on September 13, 2016. Also Forbes.com published the news titled: “Ex-Dividend Reminder: Sanderson Farms, Quest Diagnostics and Agilent Technologies” on September 28, 2016. Nasdaq.com‘s news article titled: “Quest Diagnostics’ QuestDirect Now in Colorado & Missouri” with publication date: November 23, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>